Cardiovascular and renal actions of C-type natriuretic peptide

Am J Physiol. 1992 Jan;262(1 Pt 2):H308-12. doi: 10.1152/ajpheart.1992.262.1.H308.

Abstract

Studies were performed in two groups of anesthetized dogs (n = 5 per group) to determine the cardiovascular and renal actions of synthetic C-type natriuretic peptide (CNP). Systemic infusion of CNP (group 1; 10 and 50 ng.kg-1.min-1 iv) resulted in marked cardiovascular hemodynamic effects characterized by a decrease in mean arterial pressure, cardiac output, and atrial pressures in association with a decrease in sodium excretion. Bolus administration of CNP (group 2; 5 micrograms/kg iv) to minimize cardiovascular hemodynamic changes resulted in only a transient decrease in arterial pressure. Sodium excretion decreased despite a return of arterial pressure to baseline. These biological responses were associated with increases in plasma guanosine 3',5'-cyclic monophosphate (cGMP) in both groups but with no change in urinary cGMP. With both systemic infusion or bolus administration of CNP, significant increases in plasma aldosterone were observed in association with increases in distal nephron sodium reabsorption. This study demonstrates that CNP exhibits profound systemic hemodynamic actions and is indirectly, or perhaps directly, antinatriuretic.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Absorption
  • Animals
  • Blood Pressure / drug effects
  • Cardiac Output / drug effects
  • Cardiovascular System / drug effects*
  • Cyclic GMP / blood
  • Dogs
  • Glomerular Filtration Rate / drug effects
  • Kidney / drug effects*
  • Kidney Tubules, Proximal / metabolism
  • Male
  • Natriuretic Peptide, C-Type
  • Nerve Tissue Proteins / pharmacology*
  • Renal Circulation / drug effects
  • Sodium / metabolism
  • Vascular Resistance / drug effects

Substances

  • Nerve Tissue Proteins
  • Natriuretic Peptide, C-Type
  • Sodium
  • Cyclic GMP